Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Atea Pharmaceuticals
Biotech
Atea offloads 25% of workforce, gears up for phase 3 HCV trials
Atea has laid off a quarter of its workforce so far this year as the biotech prepares to launch a phase 3 trial of its hepatitis C cocktail.
James Waldron
Mar 7, 2025 5:50am
Atea's COVID antiviral fails to halt hospitalizations in phase 3
Sep 13, 2024 10:10am
Atea rejects 'undervalued' offer from Concentra
May 30, 2023 7:51am
Concentra rebounds with a shot at COVID-19-focused Atea
May 22, 2023 11:20am
Atea dumps dengue drug as forecast R&D timelines, costs spiral
Mar 1, 2023 6:50am
Atea sticks it out with COVID antiviral and taps Merck HCV drug
Jan 7, 2022 9:50am
